Get the Stockscreener App
2.23
2.62%
-0.06
Beyondspring Inc stock is traded at $2.23, with a volume of 15,121.
It is down -2.62% in the last 24 hours and up +31.18% over the past month.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
See More
Previous Close:
$2.29
Open:
$2.29
24h Volume:
15,121
Relative Volume:
0.41
Market Cap:
$101.19M
Revenue:
$1.88M
Net Income/Loss:
$-15.57M
P/E Ratio:
-5.575
EPS:
-0.4
Net Cash Flow:
$-50.09M
1W Performance:
-11.51%
1M Performance:
+31.18%
6M Performance:
+36.81%
1Y Performance:
-9.72%
1-Day Range:
$2.2104
$2.38
1-Week Range:
$2.2104
$2.62
52-Week Range:
$0.98
$3.44
Beyondspring Inc Stock (BYSI) Company Profile
Name
Beyondspring Inc
Sector
Industry
Phone
646-528-4184
Address
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
Compare BYSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BYSI
Beyondspring Inc
|
2.23 | 101.19M | 1.88M | -15.57M | -50.09M | -0.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-21 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-02-21 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-01-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-09-21 | Initiated | Robert W. Baird | Outperform |
| Aug-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-05-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-11-21 | Initiated | BofA Securities | Buy |
| Dec-29-20 | Initiated | Evercore ISI | Outperform |
| Feb-07-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | Nomura | Buy |
| Dec-03-19 | Initiated | William Blair | Outperform |
| Jul-10-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-19 | Downgrade | Maxim Group | Buy → Hold |
| Oct-25-18 | Reiterated | Maxim Group | Buy |
View All
Beyondspring Inc Stock (BYSI) Latest News
BeyondSpring (NASDAQ:BYSI) Shares Up 30%Should You Buy? - MarketBeat
Big Cuts to U.S. Cancer Research May Create Historic Opening for Biotech Investors - Baystreet.ca
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? - The Globe and Mail
BeyondSpring reports promising phase 2 NSCLC study results By Investing.com - Investing.com South Africa
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study - GuruFocus
BeyondSpring Inc. Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting - marketscreener.com
BeyondSpring reports promising phase 2 NSCLC study results - Investing.com Australia
BeyondSpring (BYSI) Presents Promising Phase 2 Data in Lung Canc - GuruFocus
BeyondSpring (BYSI) Presents Promising Phase 2 Data in Lung Cancer Study | BYSI Stock News - GuruFocus
BeyondSpring Inc. Reports Promising Interim Phase 2 Data for Plinabulin in Metastatic NSCLC Showing 6.8 Months Median PFS and 78% Overall Survival Rate - Nasdaq
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 - GlobeNewswire
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting - TradingView
New Clinical Data: BeyondSpring's Triple Therapy Doubles Survival in Drug-Resistant Lung Cancer Patients - Stock Titan
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting | BYSI Stock News - GuruFocus
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting - GlobeNewswire
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Neutropenia Drugs Market Revenue to Surpass USD 24.2 Billion by 2033 with 4.7% CAGR - openPR.com
Should You Buy, Hold or Sell OKTA Stock Before Q1 Earnings Release? - The Globe and Mail
BeyondSpring Reports Q1 2025 Financials and Clinical Progress - TipRanks
BeyondSpring (NASDAQ:BYSI) Posts Earnings Results - MarketBeat
Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth? - Yahoo Finance
Can Saudi AI Deals Boost AMD Over NVIDIA, and Is It a Buy? - The Globe and Mail
BeyondSpring Inc. (BYSI) Reports Q1 Loss of $0.08 - StreetInsider
BeyondSpring Reports First?Quarter 2025 Financial Results and Provides Corporate Update | BYSI Stock News - GuruFocus
BeyondSpring Inc. Reports Positive Early Results for Plinabulin in Metastatic Cancer and Updates on SEED Therapeutics' Progress - Nasdaq
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
BeyondSpring, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
SEED Therapeutics Secures FDA Rare Pediatric and Orphan Drug Designations for ST-01156 - MSN
BeyondSpring (NASDAQ:BYSI) Shares Pass Below 50 Day Moving AverageTime to Sell? - MarketBeat
BeyondSpring stock hits 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa
BeyondSpring stock hits 52-week low at $1.34 amid market challenges - Investing.com India
BeyondSpring (NASDAQ:BYSI) Trading Down 3.8%Here's Why - MarketBeat
BeyondSpring’s 2024 Progress and Strategic Milestones - TipRanks
BeyondSpring stock hits 52-week low at $1.4 amid sharp decline By Investing.com - Investing.com South Africa
BeyondSpring stock hits 52-week low at $1.4 amid sharp decline - Investing.com
BeyondSpring Inc. (BYSI) reports earnings - Quartz
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones - The Manila Times
BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewswire
Beyondspring Inc Stock (BYSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):